

12-18-2018

Trypanosoma brucei PRMT1 Is a Nucleic Acid Binding Protein with a Role in Energy Metabolism and the Starvation Stress Response.

Lucie Kafková

University at Buffalo, State University of New York

Chengjian Tu

University at Buffalo


Kyle L. Pazzo

Clemson University

Kyle P. Smith

University at Buffalo, State University of New York

Erik W. Debler

*Thomas Jefferson University, Erik.Debler@jefferson.edu**See next page for additional authors*[Let us know how access to this document benefits you](#)Follow this and additional works at: <https://jdc.jefferson.edu/bmpfp> Part of the [Medical Biochemistry Commons](#), [Medical Microbiology Commons](#), and the [Medical Molecular Biology Commons](#)

Recommended Citation

Kafková, Lucie; Tu, Chengjian; Pazzo, Kyle L.; Smith, Kyle P.; Debler, Erik W.; Paul, Kimberly S.; Qu, Jun; and Read, Laurie K., "Trypanosoma brucei PRMT1 Is a Nucleic Acid Binding Protein with a Role in Energy Metabolism and the Starvation Stress Response." (2018). *Department of Biochemistry and Molecular Biology Faculty Papers*. Paper 145.
<https://jdc.jefferson.edu/bmpfp/145>

Authors

Lucie Kafková, Chengjian Tu, Kyle L. Pazzo, Kyle P. Smith, Erik W. Debler, Kimberly S. Paul, Jun Qu, and Laurie K. Read



Trypanosoma brucei PRMT1 Is a Nucleic Acid Binding Protein with a Role in Energy Metabolism and the Starvation Stress Response

Lucie Kafková,^a Chengjian Tu,^b Kyle L. Pazzo,^c Kyle P. Smith,^a Erik W. Debler,^d Kimberly S. Paul,^c Jun Qu,^b Laurie K. Read^a

^aDepartment of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA

^bDepartment of Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA

^cDepartment of Biological Sciences, Clemson University, Clemson, South Carolina, USA

^dDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

ABSTRACT In *Trypanosoma brucei* and related kinetoplastid parasites, transcription of protein coding genes is largely unregulated. Rather, mRNA binding proteins, which impact processes such as transcript stability and translation efficiency, are the predominant regulators of gene expression. Arginine methylation is a posttranslational modification that preferentially targets RNA binding proteins and is, therefore, likely to have a substantial impact on *T. brucei* biology. The data presented here demonstrate that cells depleted of *T. brucei* PRMT1 (*TbPRMT1*), a major type I protein arginine methyltransferase, exhibit decreased virulence in an animal model. To understand the basis of this phenotype, quantitative global proteomics was employed to measure protein steady-state levels in cells lacking *TbPRMT1*. The approach revealed striking changes in proteins involved in energy metabolism. Most prominent were a decrease in glycolytic enzyme abundance and an increase in proline degradation pathway components, changes that resemble the metabolic remodeling that occurs during *T. brucei* life cycle progression. The work describes several RNA binding proteins whose association with mRNA was altered in *TbPRMT1*-depleted cells, and a large number of *TbPRMT1*-interacting proteins, thereby highlighting potential *TbPRMT1* substrates. Many proteins involved in the *T. brucei* starvation stress response were found to interact with *TbPRMT1*, prompting analysis of the response of *TbPRMT1*-depleted cells to nutrient deprivation. Indeed, depletion of *TbPRMT1* strongly hinders the ability of *T. brucei* to form cytoplasmic mRNA granules under starvation conditions. Finally, this work shows that *TbPRMT1* itself binds nucleic acids *in vitro* and *in vivo*, a feature completely novel to protein arginine methyltransferases.

IMPORTANCE *Trypanosoma brucei* infection causes human African trypanosomiasis, also known as sleeping sickness, a disease with a nearly 100% fatality rate when untreated. Current drugs are expensive, toxic, and highly impractical to administer, prompting the community to explore various unique aspects of *T. brucei* biology in search of better treatments. In this study, we identified the protein arginine methyltransferase (PRMT), *TbPRMT1*, as a factor that modulates numerous aspects of *T. brucei* biology. These include glycolysis and life cycle progression signaling, both of which are being intensely researched toward identification of potential drug targets. Our data will aid research in those fields. Furthermore, we demonstrate for the first time a direct association of a PRMT with nucleic acids, a finding we believe could translate to other organisms, including humans, thereby impacting research in fields as distant as human cancer biology and immune response modulation.

Received 8 November 2018 Accepted 12 November 2018 Published 18 December 2018

Citation Kafková L, Tu C, Pazzo KL, Smith KP, Debler EW, Paul KS, Qu J, Read LK. 2018. *Trypanosoma brucei* PRMT1 is a nucleic acid binding protein with a role in energy metabolism and the starvation stress response. mBio 9:e02430-18. <https://doi.org/10.1128/mBio.02430-18>.

Editor Barbara Burleigh, Harvard T. H. Chan School of Public Health

Copyright © 2018 Kafková et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Laurie K. Read, lread@buffalo.edu.

KEYWORDS PRMT, RNA binding proteins, *Trypanosoma brucei*, arginine methylation, metabolism regulation, stress response

Trypanosoma brucei is a parasitic protozoan causing African sleeping sickness in sub-Saharan Africa. An estimated 70 million people are at risk of the infection, and WHO estimates roughly 20,000 new cases per year when likely underreporting is taken into account (1). Furthermore, animal trypanosomiasis in the African region constitutes a large economic burden. It is estimated that dealing with trypanosomiasis would result in a benefit of approximately 2.5 billion USD to livestock keepers in affected regions over a 20-year period (2). The parasite is transmitted between the mammalian hosts via an insect vector, the tsetse fly (*Glossina* spp.). Throughout its life cycle, *T. brucei* changes both its morphology and physiology to adjust to nutritional and immunological conditions encountered in the hosts. The bloodstream form (BF) that thrives in mammalian blood utilizes glycolysis, compartmentalized in a specialized organelle called a glycosome, as the main energy source (3). BF cells employ a quorum sensing mechanism to detect a high parasite load and transform to a nondividing stumpy stage that is preadapted to life in the insect vector (4). Once taken up by the fly, parasites progress through the life cycle, further changing their physiology. The procyclic form (PF) inhabiting the fly's midgut turns to proline degradation coupled to the TCA cycle to cope with the lack of glucose in its environment (5). These changes are reflected in the size of the parasite's single mitochondrion, which in PF takes up much of the cytoplasmic space, as well as in the utilization of oxidative phosphorylation, which is almost exclusively active in PF. The changes *T. brucei* undergoes through its life cycle are almost solely controlled at the posttranscriptional level, since *T. brucei* utilizes polycistronic transcription of functionally unrelated genes and subsequently generates individual mRNAs through the processes of 5' *trans*-splicing and 3' cleavage and polyadenylation (6). The major means of gene regulation are embodied in the mRNA binding proteome, which in turn is regulated by a multitude of mechanisms, including post-translational modifications (PTM). Protein arginine methylation is a PTM that disproportionately targets RNA binding proteins in *T. brucei* as well as in mammals (7–9). Arginine methylation, which in *T. brucei* affects about 15% of the proteome, is catalyzed by protein arginine methyltransferases (PRMTs) that can be classified into three types based on the end products of their catalytic activities (7, 8, 10). All three types can catalyze the formation of ω - N^G -monomethylarginine (MMA). While type III PRMTs are limited to this modification, type I PRMTs can catalyze formation of ω - N^G,N^G -asymmetric dimethylarginine (ADMA), and type II PRMTs create ω - N^G,N'^G -symmetric dimethylarginine (SDMA). *T. brucei* harbors four PRMTs that represent all three types and engage in a functional interplay (11).

T. brucei PRMT1 (*TbPRMT1*) is a type I PRMT that we previously showed catalyzes the majority of ADMA formation *in vivo* (12). *TbPRMT1* influences the functions of proteins involved in RNA editing and controls the mRNA-stabilizing and -destabilizing functions of the RNA binding protein DRBD18 in PF *T. brucei* (12–16). However, more global impacts on cell function have not been investigated, and *TbPRMT1* function has not been examined in BF *T. brucei*. *TbPRMT1* structure is highly unusual since, unlike other characterized type I PRMTs that form homodimers or homomultimers, it functions as a heterotetramer of an enzymatic subunit (ENZ) and a catalytically inactive PRMT paralog termed prozyme (PRO) (13, 17–20). The two *TbPRMT1* subunits mutually stabilize each other on the protein level, and while the PRO subunit does not carry out catalysis, it is indispensable for *TbPRMT1* function.

Here, we examine the *in vivo* role and *in vitro* properties of *TbPRMT1* using a mouse model and biochemical, cell biological, and global proteomic strategies in BF and PF *T. brucei*. Our results show that although *TbPRMT1* is not strictly needed for BF *T. brucei* growth in culture, the protein contributes to *T. brucei* virulence in an animal model. We further show that in the absence of *TbPRMT1*, the BF parasites downregulate enzymes involved in glycolysis and upregulate pathways that utilize alternative energy sources.

We quantified changes in the mRNA-bound proteome and identified several proteins whose association with mRNA is significantly altered in the *TbPRMT1*-depleted background. In the attempt to identify *TbPRMT1* *in vivo* substrates, we noted an overrepresentation of stress-related proteins associating with *TbPRMT1*. We confirmed the biological significance of this finding by demonstrating a defect in mRNA granule formation during nutritional stress in PF cells depleted for *TbPRMT1*. Finally, we show that *TbPRMT1* itself is able to associate with nucleic acids, which is a completely novel feature in this class of enzymes. Thus, the present studies reveal that *TbPRMT1* plays significant roles in trypanosome virulence, metabolism, and RNA biology.

RESULTS

Knockout of the *TbPRMT1* enzymatic subunit leads to growth retardation and decreases parasite virulence. We began by establishing whether *TbPRMT1* is essential for *T. brucei* survival in the mammalian host. As an RNAi-based knockdown had no effect on BF growth *in vitro* (data not shown), we generated a *TbPRMT1* knockout (KO) cell line in BF *T. brucei* to unequivocally determine whether the enzyme plays a role in virulence. Two alleles of the *TbPRMT1* ENZ subunit were replaced with blasticidin and puromycin resistance cassettes, whose incorporation into the genome was confirmed by PCR on genomic DNA using both *TbPRMT1* untranslated region (UTR)-based and open reading frame (ORF)-based primers (Fig. 1A). Growth of wild-type (WT) and KO cell lines was then measured over the course of 11 days, and a mild but reproducible growth phenotype was observed (Fig. 1B). To ascertain whether this phenotype could be attributed to the loss of *TbPRMT1* or whether it should be ascribed to cell-line-specific differences, we complemented the KO with the ENZ subunit of *TbPRMT1* exogenously expressed under doxycycline control. We expressed the exogenous ENZ for 2 weeks and then monitored growth over a 3-day period. We calculated doubling times of WT, ENZ KO, and ENZ KO+AB (add-back) cell lines and determined that the mild growth phenotype could indeed be attributed to the loss of *TbPRMT1* (Fig. 1C). Next we confirmed that the exogenous ENZ also restores the arginine methyl landscape of BF trypanosomes (Fig. 1D). We probed WT, ENZ KO, and ENZ KO+AB cell lysates with anti-ENZ, anti-ADMA, and anti-MMA antibodies. We saw that loss of ENZ leads to a steep increase in proteins bearing the MMA mark, a phenomenon previously observed in both mammals and *T. brucei* (11, 21). We also observed a modest decrease in proteins recognized by the anti-ADMA antibody. It is important to note that the anti-ADMA antibody recognizes only a small number of all proteins bearing the ADMA mark in the cell. In previous studies we found that while the observed decrease of proteins recognized by this antibody is modest, the increase of proteins bearing the MMA mark is quite striking (11). Upon exogenous expression of ENZ, the ADMA profile fully corresponded to the WT landscape. The MMA profile mostly corresponded to the WT landscape. Therefore, we conclude that the changes in methyl landscape in the ENZ KO cell line can be attributed to the loss of *TbPRMT1*. Having established the ENZ KO strain, we infected mice with either WT or ENZ KO *T. brucei* to determine the impact of *TbPRMT1* in a living system. We found that ENZ KO leads to a significantly prolonged life expectancy of *T. brucei*-infected mice compared to WT (Fig. 1E, $P < 0.05$). Therefore, *TbPRMT1* contributes to *T. brucei* virulence through an unknown mechanism, which may be connected to the lower growth rate of ENZ KO cells *in vitro*.

***TbPRMT1* knockout leads to changes in metabolic enzyme expression and changes mRNA association of a small subset of proteins.** RNA binding proteins are a major protein group targeted by PRMTs across the evolutionary spectrum (7–9, 22). Although arginine methylation of RNA binding proteins has mostly been shown to alter protein-protein interactions, examples of altered affinity for RNA upon modulation of arginine methylation state have been reported (9, 22–24). Since RNA binding proteins constitute the major means of regulating the *T. brucei* proteome, we asked whether the lack of *TbPRMT1* alters the association of certain proteins with mRNA. To this end, we isolated the mRNA-bound proteome from WT and ENZ KO cell lines and subjected the eluates to quantitative mass spectrometry. We anticipated that any observed changes




FIG 1 *TbPRMT1* contributes to *T. brucei* virulence. (A) (Left) Schematic representation of the knockout (KO) strategy. Arrows indicate primer placement. (Right) KO confirmation by PCR of genomic DNA from two different clones. (B) Growth of WT and ENZ KO cell lines in culture. Cumulative cell density over time was plotted. Each point represents the mean for two clones in duplicate. Error bars indicate standard deviation. (C) Doubling time of WT, ENZ KO, and ENZ KO + AB (add-back) cells either uninduced (dox-) or induced for expression of exogenous ENZ (dox+) was calculated. Two clones of each cell line were used. Mean ($n = 3$) is plotted. Error bars show standard deviation. * $P < 0.05$; ** $P < 0.005$; *** $P < 0.0005$. (D) Western blot assays in which the indicated antibodies were used to assay levels of endogenous and exogenous ENZ and visualize the methyl landscape of indicated cell lines. * marks a nonspecific band recognized by the anti-ENZ antibody. HSP70 is a load control. (E) Virulence assay. Mice were infected with the WT or ENZ KO strain. Time of death postinfection is plotted.

in the mRNA-bound proteome could be attributed to either altered mRNA association or altered protein abundance in the cell. In order to discriminate between these two possibilities, we first established steady-state abundances of proteins in WT and ENZ KO cell lines by quantitative mass spectrometry analysis. We identified 4,856 proteins out of the 9,598 currently annotated in the TriTryp database as protein coding. We saw that 385 proteins decreased in abundance (>1.5 -fold, $P < 0.05$) and 167 proteins increased their abundance (>1.5 -fold, $P < 0.05$) in the KO compared to WT (see Table S1 in the supplemental material). We confirmed these changes by Western blotting for several proteins that did not change in abundance; MRB800, which decreased in abundance; and UMSBP1, which increased in abundance (Fig. 2A and Fig. S1). Further analysis of the data set revealed alterations in the levels of proteins involved in various aspects of *T. brucei* biology such as cell division, DNA repair and replication, RNA synthesis and processing, translation, the ubiquitin system, and vesicular transport. We also noted numerous remarkable alterations in the abundances of proteins involved in energy metabolism, some of which suggested possible pathway coregulation and life cycle-specific regulation. For example, ENZ KO leads to upregulation of several enzymes in the proline degradation pathway (Fig. 2B and Table 1). Interestingly, the mRNAs encoding all of the enzymes needed to obtain energy from the oxidation of proline to succinate are bound by a common RBP, DRBD3 (25). We identified significant overlap




FIG 2 *TbPRMT1* knockout leads to metabolic reprogramming. (A) Western blot confirmation of changes in protein levels detected by quantitative mass spectrometry. (Top) Representative Western blot of indicated proteins. Load control, whole-protein Revert staining. (Bottom) Quantification of protein levels. An equation of trendline describing expected antibody signal per Revert signal in WT cells was obtained (Fig. S1). Expected antibody signal for each experimental sample was calculated using Revert signal. Shown is the mean from two biological and two technical replicates of actual/expected signal, with error bars denoting standard deviation. *P* values were calculated using a two-tailed *t* test. **, *P* < 0.005; ***, *P* < 0.0005. (B) Schematic representation of metabolic changes in ENZ KO cells. Green, pathways upregulated in ENZ KO. Red, pathways downregulated in ENZ KO. Red crosses indicate positions of major blocks in the pathways. Dashed green circle indicates upregulated membrane transporter. CS, citrate synthase; 2-Ket, α -ketoglutarate; GLU, glutamic acid; GLN, glutamine. (C) Western blot of bloodstream-form WT (WT BF), ENZ KO BF, and procyclic-form strain 29-13 (WT PF) cells using an antibody that recognizes PAD2. Arrow indicates PAD2 signal. Load control, whole-protein Revert staining.

between DRBD3-bound transcripts and proteins upregulated in ENZ KO (*P* = 0.009), suggesting that this RBP may mediate a subset of the changes observed in Table 1. The proline degradation pathway is typically utilized in PF *T. brucei* cells that lack access to glucose (5), leading us to examine other metabolic pathways whose utilization is altered during the *T. brucei* life cycle. We observed an upregulation of certain subunits of respiratory chain complexes and farnesyl pyrophosphate synthase, which is involved in synthesis of CoQ (Table 1). The most prominent increase in abundance was noted in the citric acid cycle, namely, in the level of citrate synthase, which increased 10-fold. We also noted a marked decrease in enzymes participating in the major pathway of energy production in BF *T. brucei*: glycolysis. Specifically, hexokinase, the enzyme responsible for glucose commitment to glycolysis, decreased in abundance to about 50% of WT levels. Similar decreases were noted in the levels of glucose-6-phosphate isomerase, an enzyme working directly downstream of hexokinase, and in alanine aminotransferase. Alanine aminotransferase is responsible for conversion of pyruvate to alanine, a pathway that is extensively utilized in BF trypanosomes (26). We also noticed a decrease in several enzymes with putative roles in inositol metabolism (Table 1, "other metabolism-related genes"). Three out of four *T. brucei* fatty acyl CoA synthetases and glycerol-3-phosphate acyltransferase decreased in abundance, indicating a decrease in the rate of *de novo* lipid synthesis that utilizes free fatty acids and glycerol. Possibly related to

TABLE 1 Metabolism-related proteins that were identified by mass spectrometry as having altered abundance in ENZ KO cell line

Gene ID	Product name	KO/WT	P value
Proline metabolism			
<i>Tb927.10.13120</i>	<i>TbMCP14</i> mitochondrial proline transporter	2.13	4.25E−02
<i>Tb927.7.210</i>	Proline dehydrogenase	1.95	1.01E−05
<i>Tb927.9.5900</i>	Glutamate dehydrogenase	1.77	3.93E−04
<i>Tb927.11.9980</i>	Oxoglutarate dehydrogenase E1 component	1.58	1.96E−03
Glucose metabolism			
<i>Tb927.10.2020</i>	Hexokinase (<i>TbHK2</i>) ^a	0.43	7.63E−03
<i>Tb927.1.3830</i>	Glucose-6-phosphate isomerase	0.58	9.28E−05
<i>Tb927.1.3950</i>	Alanine aminotransferase	0.62	4.38E−03
TCA cycle and respiration			
<i>Tb927.11.9980</i>	Oxoglutarate dehydrogenase E1 component	1.58	1.96E−03
<i>Tb927.10.13430</i>	Citrate synthase	10.90	1.18E−02
<i>Tb927.10.14000</i>	Aconitase	1.87	1.39E−03
<i>Tb927.9.5960</i>	Succinate DH-complex II	1.85	1.55E−02
<i>Tb927.8.3380</i>	Succinate DH-complex II	1.88	2.63E−03
<i>Tb927.2.4700</i>	Succinate DH-complex II	1.52	1.67E−02
<i>Tb927.10.3040</i>	Succinate DH-complex II	1.94	2.09E−02
<i>Tb927.10.12540</i>	Complex I subunit	2.76	1.78E−02
<i>Tb927.10.13620</i>	Complex I subunit	0.39	6.51E−03
<i>Tb927.7.6350</i>	Complex I subunit	5.10	7.17E−03
<i>Tb927.11.15820</i>	Complex I subunit	1.95	1.26E−02
<i>Tb927.11.6980</i>	Complex I subunit	0.40	1.91E−04
<i>Tb927.1.4100</i>	Complex II subunit	1.69	6.97E−03
<i>Tb927.9.14200</i>	Complex II subunit	2.86	3.61E−02
<i>Tb927.2.3610</i>	Complex V subunit ^a	1.98	2.38E−02
Other metabolism-related genes			
<i>Tb927.7.3360</i>	Farnesyl pyrophosphate synthase	4.71	6.95E−03
<i>Tb11.v5.0178</i>	Glutamine synthetase	4.59	7.32E−04
<i>Tb927.8.6170</i>	Transketolase ^a	2.67	2.71E−04
<i>Tb927.3.4850</i>	Mitochondrial enoyl-CoA hydratase	2.37	1.35E−02
<i>Tb927.10.3100</i>	Glycerol-3-phosphate acyltransferase ^a	1.70E−06	6.77E−03
<i>Tb927.9.4190</i>	Fatty acyl CoA synthetase 1	0.60	7.82E−06
<i>Tb927.9.4200</i>	Fatty acyl CoA synthetase 2	0.63	2.70E−06
<i>Tb927.9.4210</i>	Fatty acyl CoA synthetase 3	0.39	4.38E−04
<i>Tb927.10.14170</i>	Aquaglyceroporin 2	0.46	1.59E−05
<i>Tb927.9.6350</i>	Inositol monophosphatase ^a	5.72E−04	3.58E−02
<i>Tb927.3.4570</i>	<i>N</i> -Acetylglucosaminyl transferase component GPI1	0.01	3.94E−02
<i>Tb927.10.4780</i>	GPI inositol deacylase	0.22	4.07E−02
<i>Tb927.3.2610</i>	GPI inositol deacylase 2	0.32	1.87E−04
<i>Tb927.8.6390</i>	Lysophospholipase	0.62	2.52E−02
<i>Tb927.10.6440</i>	Phosphomannomutase	0.67	3.67E−02

^aArginine methylation identified in proteome-wide screen (7, 8; unpublished data).

these changes could be the roughly 50% decrease in aquaglyceroporin 2 (AQP2) channel abundance. AQP2 is a glycerol transporter residing in the *T. brucei* cell membrane that has been linked to drug resistance in African trypanosomes (27).

Overall, the observed changes in metabolism resembled those typically observed during the transition from BF to PF. However, when we compared the entire data set to proteins previously shown to be up-/downregulated in PF or BF, we did not see a significant overlap with those that change upon ENZ KO (28). We did, however, observe an increase in PAD2, a protein involved in conveying the differentiation signal in the BF-to-PF life cycle transition (29). PAD2 is absent from the long slender BF stage, increases in abundance in the stumpy stage, and remains on the surface once the cells progress to the PF stage. We wanted to verify the increase in PAD2 in BF upon ENZ KO through Western blotting using anti-PAD2 antibodies (29). We were unable to quantify the increase due to the absence of PAD2 signal in our WT BF cells. However, we do clearly observe a detectable amount of PAD2 in ENZ KO cells, validating the increase in this key differentiation molecule (Fig. 2C). Overall, we conclude that the loss of ENZ leads to a dysregulation of *T. brucei* metabolism. This effect may be achieved through

TABLE 2 Proteins changing their mRNA association in ENZ KO cells

Protein ID	Bound to mRNA		Whole-cell proteome		Lueong et al. (30) FDR	Product description ^a
	KO/WT ratio	P value	KO/WT ratio	P value		
<i>Tb927.10.5620</i>	6.0	6.E−04	1.00	0.84	0.18	Fructose-bisphosphate aldolase, glycosomal
<i>Tb927.10.4430</i>	2.0	3.E−02	NA	NA	3.3E−03	PUF1, posttranscriptional repressor
<i>Tb927.9.10400</i>	1.8	2.E−02	0.92	0.11	8.1E−03	Nucleolar protein of unknown function
<i>Tb927.10.10280</i>	1.7	1.E−02	1.22	1.E−02	4.4E−02	<i>TbBBP268</i>
<i>Tb927.9.4080</i>	0.6	5.E−03	1.13	0.16	2.5E−03	Stumpy formation signaling pathway protein
						HYP2, posttranscriptional activator
<i>Tb927.6.5010</i>	0.6	8.E−03	0.50	0.15	5.3E−03	Putative nuclear protein, posttranscriptional repressor
<i>Tb927.9.12360</i>	0.6	3.E−03	0.58	6.E−03	6.3E−03	RBP35, posttranscriptional repressor
<i>Tb927.11.10810</i>	0.5	2.E−03	NA	NA	8.7E−03	PUF11
<i>Tb927.9.15290</i>	0.6	3.E−03	0.25	0.42	1.0E−02	CHAT domain-containing protein, putative
<i>Tb927.8.710</i>	0.7	1.E−02	0.01	0.14	2.3E−02	DRBD17
<i>Tb927.10.7310</i>	0.1	2.E−04	0.39	0.59	2.7E−02	Terminal uridylyltransferase 3
<i>Tb927.8.750</i>	0.6	1.E−02	1.90	6.E−09	3.3E−02	NOPP44/46-2
<i>Tb927.8.760</i>	0.4	8.E−03	1.12	0.41	5.0E−02	NOPP44/46-1
<i>Tb927.11.4380</i>	0.4	4.E−02	0.09	0.15	NA	ATP-dependent RNA helicase, putative
<i>Tb927.8.4500</i>	0.5	1.E−03	0.36	0.15	3.2E−04	eIF4G5, posttranscriptional activator
<i>Tb927.11.14590</i>	0.4	4.E−04	0.37	0.16	1.2E−02	eIF4G5-interacting protein

^aPosttranslational activator/repressor function determined by RNA tethering screen in Erben et al. (53).

regulatory mechanisms that play a role in life cycle progression or alternatively may be a compensatory effect as the cells cope with the stress of ENZ loss.

Having established steady-state levels of proteins in our WT and ENZ KO cell lines, we proceeded to quantify changes in the mRNA-bound proteome. WT and KO cells were UV cross-linked, and mRNA was affinity purified using oligo(dT)-coated magnetic beads (30). The mRNA with bound proteins was eluted off the beads, and proteins were quantified by mass spectrometry (Table S2). We identified 234 proteins, including 129 out of 155 proteins that were previously identified as mRNA binding in BF *T. brucei* by Lueong et al. (30). We observed significant changes in the abundance of 16 proteins (>1.5-fold, $P < 0.05$) in ENZ KO compared to WT parasites (Table 2). Of these, 14 proteins were also identified in our whole-cell proteome analysis (Table S1). Only the levels of RBP35 (*Tb927.9.12360*) and Nopp44/46-2 (*Tb927.8.750*) significantly changed on the whole-cell level, although eight proteins showed a trend that suggested a possible change but did not pass the significance criteria (Table 2). To verify the mRNA-bound proteome data set, we repeated the mRNA purification experiment in biological triplicate and detected selected proteins by Western blotting (Fig. 3A). Based on available antibodies, we chose to assay levels of ZFP3 (*Tb927.3.710*, unchanged), NOPP44/46-1 (*Tb927.8.760*, decreased), and aldolase (*Tb927.10.5620*, increased). The aldolase Western blot did not reveal a significantly increased association with mRNA in the ENZ KO cell line, although the quantification showed a trend consistent with a slight increase. This result was not surprising considering that, unlike ZFP3 and NOPP44/46-1 proteins, which are both involved in nucleic acid metabolism, aldolase is an extremely abundant metabolic enzyme. Thus, the increased mRNA association of aldolase in our experiment may be due to contamination of *TbPRMT1* KO samples. In contrast, Western blot analysis confirmed our mass spectrometry results for ZFP3 and NOPP44/46-1, demonstrating unchanged levels for the former and a decrease of the latter to less than 30% of WT levels. Interestingly, we previously showed that NOPP44/46-1 is heavily decorated by ADMA, consistent with an important role for *TbPRMT1* in its activity (7).

Having verified the data set, we more closely analyzed the proteins exhibiting altered mRNA association in ENZ-depleted cells. We first asked whether these proteins have commonalities in their subcellular localization by examining data from the TrypTag project. Interestingly, out of the 8 proteins tagged to date, 7 localize at least partially to cytoplasmic punctae in PF *T. brucei* (*Tb927.10.4430*, *Tb927.9.4080*,




FIG 3 Confirmation of mRNA-bound proteome changes. (A) Western blot confirmation of mRNA-bound protein levels. (A) (Top) Representative Western blot of indicated proteins. IN, input; EL, elution. Indicated is % of total sample. Load control, whole-protein Revert staining. (Bottom) Quantification of protein levels. Antibody signals were normalized to Revert and to the mean signal of the WT sample. Mean from biological triplicates is plotted with error bars denoting standard deviation. P values calculated using two-tailed t test. **, $P < 0.005$. (B) Immunolocalization of NOPP44/46-1 by immunofluorescence with a NOPP44/46-1-specific antibody. Large panel shows merged DAPI and NOPP44/46-1 signal. (C) $[^{35}\text{S}]$ methionine labeling of nascent proteins. Labeled cells were lysed, and proteins were separated by SDS-PAGE. Coomassie, protein load; Radiograph, nascent protein signal. * indicates proteins that changed expression.

Tb927.9.12360, Tb927.11.10810, Tb927.8.710, Tb927.8.4500, and Tb927.11.14590). We were also intrigued by the change in mRNA association of eIF4G5, its interacting protein G5-IP, and two members of the NOPP44/46 family, given the reported translation-related functions of these proteins. eIF4G5 forms a complex with eIF4E6 and G5-IP, a protein with similarity to capping enzymes. This complex has affinity for capped mRNAs, but its depletion does not significantly decrease the overall translation rate (31). NOPP44/46 is a trypanosome-specific protein family that bears extensive, life cycle-regulated tyrosine phosphorylation and has been implicated in ribosomal 60S subunit maturation (32). Since NOPP44/46-1 is known to shuttle between nucleus and cytoplasm, we first wanted to determine whether the decrease in NOPP44/46-1 mRNA binding could be due to mislocalization (33). We immunolocalized the protein but did not observe any change between the WT and ENZ KO cell lines (Fig. 3B). Given the potential roles of the above-mentioned proteins in translation, we next asked whether ENZ KO leads to an altered translation rate of all or a subset of proteins. We pulsed the cells with $[^{35}\text{S}]$ methionine and separated the nascent proteins by SDS-PAGE. We detected a reproducible decrease in translation of an ~ 50 -kDa and an ~ 38 -kDa protein but did not see any overall translation defect (Fig. 3C). It is important to note that this




FIG 4 Proteins identified in PRO-MHT purification. (A) GO term enrichment was acquired from TriTryp-db.org. *P* values are Bonferroni corrected. (B) Venn diagram of proteins present in PRO purification and proteins overrepresented in stress granules (34). *P* value calculated using R p-hyper function.

assay lacks the resolution to visualize low-abundance proteins; therefore, it is quite possible that the number of proteins whose translation rate is affected exceeds the two easily visualized proteins. We conclude that the loss of *TbPRMT1* alters the mRNA binding capacity of a small number of cytoplasmic proteins, which in turn may lead to specific impacts on mRNA translation.

***TbPRMT1* is necessary for an efficient *T. brucei* starvation stress response.** To begin to distinguish secondary effects of *TbPRMT1* depletion from the primary affected pathways, we need to determine possible *TbPRMT1* substrates. Since our antibodies are not specific enough to immunoprecipitate either ENZ or PRO subunit, we attempted to purify exogenously expressed PRO-Myc-His-TAP (PRO-MHT) from BF *T. brucei* to identify associated proteins that may be substrates. We were unable to achieve sufficient expression for proteomic analysis in BF and so switched to PF. We successfully expressed PRO-MHT and purified associated proteins (see Table S3 in the supplemental material). Complexes were eluted by TEV protease cleavage to minimize contaminants, and cells in which PRO-MHT expression was not induced were used as a negative control. We refined our data set by eliminating all proteins that were identified by $<2.5 \times$ peptides over the negative control, using the replicate with lower peptide count for that specific protein. Applying this criterion, we identified enriched biological process GO terms for our data set. We observed a significant enrichment for proteins involved in metabolic processes and various levels of gene expression, findings that supported our previous data indicating *TbPRMT1* involvement in regulation of *T. brucei* metabolism (Fig. 4A). Unsurprisingly, when we looked at molecular function GO terms,

TABLE 3 Stress-granule enriched RNA binding proteins present in PRO-MHT purification^a

Protein ID	No. of peptides identified			Product name	R methylation
	Rep1	Rep2	Neg ctrl		
Tb927.10.3560	501	622		PRO	
Tb927.1.4690	216	274		ENZ	
Tb927.9.12510	20	35	5	ATP-dependent DEAD/H RNA helicase	ADMA/DMA/MMA
Tb927.11.550	20	31	8	Hypothetical protein SCD6.10	
Tb927.10.2370	19	15		Lupus La protein homolog	
Tb927.4.2040	15	15		DNA/RNA-binding protein Alba 3	DMA/MMA
Tb927.9.13990	14	17		RNA-binding protein, putative	
Tb927.11.14220	12	17	3	Hypothetical protein, conserved	
Tb927.10.6060	11	9		Universal minicircle sequence binding protein 2	
Tb927.11.2250	6	24		HYP11	ADMA
Tb927.10.6050	6	16		Clathrin heavy chain	
Tb927.10.11760	5	8		Pumilio/PUF RNA binding protein 6	ADMA
Tb927.7.4900	4	7		5'-3' exoribonuclease A	SDMA/MMA
Tb927.6.640	4	6		ApaH-like phosphatase ALPH1	
Tb927.8.990	3	8		RNA-binding protein 33	ADMA/SDMA
Tb927.10.14950	3	7		Zinc finger CCCH domain-containing protein 40	
Tb927.6.1870	3	5		Eukaryotic translation initiation factor 4E-4	
Tb927.4.410	2	5		CAF 40	
Tb927.8.1500	2	3		Hypothetical protein, conserved	

^aDMA, dimethylarginine (ADMA/SDMA could not be determined); ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; MMA, monomethylarginine.

the overwhelming majority of identified proteins fell into the RNA binding protein category (Fig. 4A). A single protein was identified in common between the proteins that changed their mRNA association and proteins that copurify with *TbPRMT1*: a nucleolar protein with unknown function (*Tb927.9.10400*). Although not identified as methylated on arginine residues in our proteome-wide screen (7, 8; also unpublished data), the *Tb927.9.10400* sequence contains multiple RGG motif repeats, which are typically targeted by arginine methylation, making *Tb927.9.10400* a promising target for future studies. One finding that caught our eye was the significant overlap of proteins that copurify with *TbPRMT1* and proteins that are enriched in *T. brucei* starvation granules (34) (Fig. 4B) ($P = 5.3 \times 10^{-8}$) (Table 3). This includes SCD6 (*Tb927.11.550*), a stress-related protein that was previously reported to copurify with *TbPRMT1* (35). Association of *TbPRMT1* with starvation stress-related granules was particularly striking since the PRO subunit of *TbPRMT1* itself was enriched in a recent proteomic analysis of stress granules (34). To investigate a possible role of *TbPRMT1* in stress granule formation, we utilized a PF ENZ RNAi cell line that efficiently ablates PRO and ENZ protein levels when induced by doxycycline (11). Either uninduced or RNAi-induced cells were starved by a two-hour incubation in PBS, and mRNA was subsequently visualized by oligo(dT) fluorescent *in situ* hybridization (FISH) (Fig. 5A). We classified the cells as either stressed (clearly containing RNA granules), intermediate (some granulation might be present), or normal (mRNA distributed evenly throughout cytoplasm) (Fig. 5B, lower panel). We observed a statistically significant decrease in cells that were able to form stress granules upon *TbPRMT1* depletion (Fig. 5B, upper panel). Together, these data demonstrate a role for *TbPRMT1* in starvation stress granule formation in PF *T. brucei* and suggest potential substrates that may contribute to this effect.

***TbPRMT1* directly binds to nucleic acid.** The effect of *TbPRMT1* on stress granule formation led us to investigate the possibility that *TbPRMT1* might itself be able to associate with RNA. This notion was supported by a recently reported mRNA-bound proteome study in which more PRO peptides were purified with the mRNA than in the negative control, although the significance criterion was not met (30). To investigate whether *TbPRMT1* has RNA binding properties, we began by analyzing the association of *TbPRMT1* with mRNA *in vivo*. We attempted to use our antipeptide *TbPRMT1* antibodies; however, the results were inconclusive due to the interference of nonspecific bands (data not shown). Therefore, we utilized our PRO-MHT cell line to purify the




FIG 5 *TbPRMT1* is necessary for mRNA migration to starvation stress granules. (A) mRNA was visualized by oligo(dT) FISH in the PF ENZ RNAi cell line. Uninduced cells (dox-) or RNAi-induced cells (dox+) were either cultured in medium (Normal) or nutritionally starved (Stress). mRNA was visualized by FISH (red), and DNA was stained with DAPI (blue). (B) Cells were divided into normal (N), intermediate (I), or granule (G) categories (for examples, see bottom panel) and counted. Means for two biological replicates of 300 to 500 cells each were plotted, and *P* values were calculated using the chi-squared test. ***, *P* < 0.0005. Error bars show the range of values from each experiment.

mRNA-bound proteins. Due to the presence of the protein A moiety in the TAP tag, the secondary anti-rabbit IgG antibody strongly recognized the tagged protein (Fig. 6). We saw a clear association of PRO-MHT with mRNA as well as the presence of our positive control, DRBD18. Our negative control, p22, was not present in the final eluate. Therefore, we conclude that PRO associates with mRNA *in vivo*. To confirm that PRO




FIG 6 *TbPRMT1* binds mRNA *in vivo*. mRNA was purified from PF cells expressing PRO-MHT, which were either left untreated (UV X-link -) or UV cross-linked (UV X-link +) prior to lysis. Western blotting was used to detect the indicated proteins in input (IN), oligo(dT) bead flowthrough (FT), and oligo(dT) bead elution (EL). Percentages loaded are indicated. Positive control, DRBD18; negative control, p22. Arrows indicate migration of target proteins.

directly associates with RNA, we turned to *in vitro* methods. Since our attempts to identify *in vivo* *TbPRMT1* mRNA targets were unsuccessful, we utilized a 102-nt ^{32}P -labeled pBluescript SK- plasmid RNA. We generated recombinant *TbPRMT1* heterotetramer by ENZ and His-PRO coexpression in *Escherichia coli* followed by nickel affinity purification of the complex as described previously (12). Individual *TbPRMT1* subunits were expressed as His-ENZ or His-PRO separately and purified. We incubated the RNA with *TbPRMT1*, individual *TbPRMT1* subunits, and other *T. brucei* PRMTs; UV cross-linked the samples; separated them by SDS-PAGE; and visualized RNA-bound complexes (Fig. 7A). We observed no RNA binding when only the ENZ *TbPRMT1* subunit was present, although this result should be viewed with caution, since the ENZ subunit is difficult to purify by itself and is prone to aggregation. Importantly, we saw clear RNA binding of the PRO subunit both incubated alone with RNA and within the context of the entire *TbPRMT1* heterotetramer. We also observed binding of *TbPRMT7*, a type III PRMT that was enriched in the published *T. brucei* mRNA-bound proteome to a similar degree as *TbPRMT1* (30). *TbPRMT6* was not found cross-linked to RNA, suggesting that *in vitro* RNA binding is not a default feature of all PRMTs. Next, we wanted to utilize another, more native method to confirm that *TbPRMT1* binds RNA *in vitro*. We incubated increasing concentrations of *TbPRMT1* or its PRO subunit with labeled RNA and resolved the reaction mixtures by native PAGE, resulting in an electrophoretic mobility shift (EMSA) of protein-bound RNA. We saw a distinct shift of RNA migration at the highest protein concentrations (2 and 4 μM) (Fig. 7B). This suggests a relatively low affinity of *TbPRMT1* for pBluescript RNA but confirms *TbPRMT1* RNA binding ability. Some proteins exhibit affinity for specific polynucleotide sequences, and the *in vivo* mRNA binding activity of *TbPRMT1* suggested it could exhibit high affinity for poly(A). To investigate whether *TbPRMT1* has a preference for specific polynucleotides, we performed the *in vitro* RNA cross-linking assay using a 47-nt transcript of pBluescript sequence in the presence of increasing amounts of unlabeled poly(A), poly(C), poly(U), and poly(G) to determine their abilities to compete with the labeled probe for binding to *TbPRMT1* (Fig. 7C). In these assays, PRO exhibited a preference for poly(U) and poly(G) but little binding to poly(A) or poly(C). Considering the low affinity of *TbPRMT1* for RNA, we wanted to determine whether *TbPRMT1* binds RNA specifically or whether the binding ability extends to all nucleic acids. We incubated *TbPRMT1* with labeled RNA in the presence of unlabeled RNA or DNA competitor. We saw that the two competitors performed equally; therefore, we conclude that *TbPRMT1* has nucleic acid binding ability (Fig. 7D). In another study (H. Hashimoto, L. Kafková, K. Jordan, L. K. Read, and E. W. Debler, submitted for publication), we determined that *TbPRMT1* tetramerization is necessary for *TbPRMT1* methylation activity. We thus wanted to test whether the tetramerization also influences *TbPRMT1* RNA binding properties. We performed the RNA cross-linking assay on a battery of mutants that were unable to tetramerize (Fig. 7E). We observed that while tetramerization is not required for RNA binding, specific mutations in either the ENZ or PRO subunits of *TbPRMT1* decrease the




FIG 7 *TbPRMT1* binds mRNA *in vitro*. (A) 32 P-labeled pBluescript SK[−] RNA was cross-linked to equimolar amounts of the indicated recombinant proteins. PRMT molarity was calculated per dimer. Reaction mixtures were treated with RNase A and resolved by SDS-PAGE. The dried, Coomassie blue-stained gel was exposed to a phosphorimager screen (Radiograph). Positive control, MBP-MRB8180; negative control, His-p22. (B) 32 P-labeled pBluescript SK[−] RNA was incubated with increasing amounts of recombinant *TbPRMT1* or PRO. Reaction mixtures were resolved by native PAGE, and the dried gel was visualized by phosphorimager screen exposure. #, free RNA; *, PRMT/RNA complex; ~, possible PRMT/RNA aggregate. (C) UV cross-linking assay performed as in panel A in the presence of unlabeled oligo(N) competitor. (D) UV cross-linking assay performed as in panel A in the presence of unlabeled RNA/DNA competitor. (E) UV cross-linking assay performed as in panel A utilizing a battery of *TbPRMT1* mutants. Table at bottom of panel E describes the mutations. P or E in the superscript designates whether the mutation was in the PRO or ENZ subunit, respectively.

RNA binding potential of the protein complex. The finding that specific mutations are able to decrease *TbPRMT1* RNA affinity strongly suggests that *TbPRMT1* RNA binding is a specific and biologically relevant property of the enzyme, and it opens a window to further studies that will determine the residues directly involved in *TbPRMT1* RNA binding.

DISCUSSION

Arginine methylation is a ubiquitous posttranslational modification that influences a broad spectrum of eukaryotic cellular processes (36–41). The enzymes catalyzing this modification, PRMTs, are astonishingly well conserved throughout the eukaryotic kingdom. The enzymatic subunit of *TbPRMT1*, for example, shares 53% amino acid sequence identity with human PRMT1, a homology quite unusual between organisms with such evolutionary distance between them. In this study, we provide biochemical

and cell biological characterization of *TbPRMT1*. We show that in BF *T. brucei*, *TbPRMT1* promotes virulence in the animal model, influences energy metabolism, and changes mRNA association of a small subset of proteins. In insect-stage parasites, loss of *TbPRMT1* significantly hinders the parasite's ability to form mRNA-containing cytoplasmic granules as a response to starvation stress. Furthermore, we show that *TbPRMT1* is itself able to bind nucleic acids both *in vitro* and *in vivo*.

The virulence decrease of ENZ KO trypanosomes is interesting in the context of a phenotype observed in *Leishmania major*, a parasite closely related to *Trypanosoma* species. In contrast to what we observed in *TbPRMT1* KO parasites, deletion of the *LmjPRMT7* gene led to an increase in virulence, while overexpression caused decreased lesion progression in a mouse model (42). PRMTs are well known to engage in interplay in both *T. brucei* and human cells (11, 21). Depletion of PRMT1 in both cell types causes a massive increase in MMA, which in *T. brucei* PF cells is attributed to *TbPRMT7* activity (11). While the opposing effects of downregulating the two proteins could be a coincidence, especially considering that the data originated from different species, it is plausible that the virulence decrease we observe in the absence of *TbPRMT1* results from increased *TbPRMT7* activity.

Trypanosomes extensively modulate their energy metabolism throughout their life cycle as well as in response to available nutrients (43, 44). In ENZ KO cells, we observed a number of alterations in metabolic enzyme abundance that are reminiscent of metabolic changes observed during *T. brucei* life cycle progression, namely, a decrease in glycolytic enzymes and an increase in components of the citric acid cycle and the proline degradation pathway. This prompted us to assess the ability of ENZ KO cells to undergo citrate-/cis-aconitate-induced *in vitro* differentiation from BF to PF. We did not observe any difference in the rate at which the cells acquired a procyclin coat or lost VSG coating compared to WT parasites (data not shown). This result could suggest that the observed changes are a result of slow growth rather than a reflection of interference with life cycle progression regulation (45, 46). However, it is important to note that the citrate/cis-aconitate differentiation method forces the parasites to progress from BF to PF, skipping the stumpy stage, which our laboratory strain is not able to produce. Both the observed ~50% decrease in mRNA binding of HYP2 (*Tb927.9.4080*), a protein identified in a screen aimed at factors driving stumpy formation, and the increase in PAD2 protein levels in ENZ KO cells suggest possible *TbPRMT1* involvement in BF to stumpy-stage progression (4). Furthermore, the observed defect in starvation granule formation in *TbPRMT1*-depleted cells hints at a possible defect in a life cycle progression through impaired response to the nutrient-poor environment that is naturally found in fly midgut and salivary glands. It is known that the differentiation of *Trypanosoma cruzi*, a close relative of *T. brucei*, from proliferative epimastigotes to infective growth-arrested metacyclic trypomastigotes requires nutritional stress as one of the signals (47, 48). To better understand the role of *TbPRMT1* in the life cycle progression of *T. brucei*, it will be necessary to generate a pleomorphic *T. brucei* cell line lacking *TbPRMT1* and observe the ability of these cells to progress through the natural life cycle in the animal and fly hosts.

To begin understanding the direct effects of *TbPRMT1*-mediated methylation, it is important to identify *TbPRMT1* substrates. Some of the observed effects are likely caused by regulation of RNA binding proteins either by direct methylation or by methylation of their binding partners. Our data show changes in the mRNA association of several RNA binding proteins. PUF1 and *Tb927.9.10400* exhibit increased association with RNA in the absence of *TbPRMT1*. PUF1 depletion causes only minor changes in PF and BF gene expression, although this was investigated only by the relatively insensitive microarray approach, and the role of PUF1 in other *T. brucei* life cycle stages was not investigated (49). PUF1 is unlikely to be a direct target of *TbPRMT1*, since our proteome-wide screens did not identify arginine methylation of PUF1, nor was PUF1 found associated with *TbPRMT1* (7, 8; unpublished data). *Tb927.9.10400* is a nucleolar protein of unknown function (50). Despite the absence of *Tb927.9.10400* in our proteome-wide methylation screen, the protein sequence contains numerous RGG

repeats that are typically targeted by arginine methylation. Furthermore, *Tb*927.9.10400 was in the top 5% of PRO-MHT-interacting proteins based on the spectral count, making it a promising candidate for future studies.

None of the proteins that decreased their mRNA association upon ENZ KO were found interacting with *Tb*PRMT1. Nevertheless, the decrease in HYP2 mRNA binding that we observed in ENZ KO cells is intriguing. HYP2 contains a DksA zinc finger, a motif involved in nutritional status and quorum sensing responses in prokaryotes, and has been identified as a part of a quorum sensing signaling cascade that plays a role in stumpy-stage formation in *T. brucei* (4). The HYP2 protein sequence contains a number of arginines in the RG context, making it a potential target of arginine methylation. It is also possible that the HYP2-mRNA interaction is indirectly affected by *Tb*PRMT1 activity. HYP11 (*Tb*927.11.2250) was also implicated to play a role in stumpy formation (4, 51). HYP11 bears an ADMA mark, copurifies with *Tb*PRMT1, has RNA binding properties, and is enriched in stress granules (4, 30, 34), strongly suggesting that HYP11 is a primary *Tb*PRMT1 target. While HYP11 mRNA binding is not changed in our screen, it is possible that arginine methylation of HYP11 influences HYP2 mRNA binding or changes the composition of an HYP11-containing ribonucleoprotein, ultimately altering mRNA fate. It is important to note that our mRNA binding screen is likely biased toward identification of mRNA association changes in proteins with a narrow specificity toward a small subset of mRNAs, since changes in specificity of proteins with a large pool of bound mRNAs would not result in a statistically significant change in overall mRNA binding.

Other regulators of mRNA fate that could be affected by arginine methylation include DRBD3 and SCD6. DRBD3 is essential in PF cells and acts as a stabilizing factor of a small subset of mRNAs, some of which undergo stage-specific regulation (52). Considering that levels of DRBD3 remain constant between PF and BF cells, it is possible that stage-specific regulation is achieved through PTM decoration (52). Interestingly, among DRBD3 targets are the enzymes constituting the proline degradation pathway, several of which are upregulated in ENZ KO cells. DRBD3 was annotated as a posttranscriptional activator based on a high-throughput tethering assay (53). DRBD3 was not found methylated in our screen; however, it does harbor an RGG motif that is typically targeted by PRMTs. Starvation stress alters the composition of DRBD3-associated ribonucleoprotein complexes and causes DRBD3 to localize into cytoplasmic granules (54). Among DRBD3-interacting proteins are PABP1, PABP2, and NOT1, all of which copurify with *Tb*PRMT1 and are also overrepresented in starvation stress granules (54). It is plausible that DRBD3 function is regulated through methylation of these proteins. Furthermore, DRBD3 appears as a possible mechanistic link between stage-specific metabolism regulation and starvation stress response. SCD6/RAP55 is a translational repressor with a function in stress granule formation in yeast and mammals (55–57). SCD6 function is modulated by HMT1/PRMT1 in yeast and mammals, and in *T. brucei* SCD6 strongly interacts with *Tb*PRMT1 and is methylated on three arginine residues (35, 58–61). Unlike SCD6 in other organisms, *Tb*SCD6 does not seem to be necessary for formation of mRNA-containing granules under starvation conditions (35). However, *Tb*SCD6 is a component of processing bodies, which are constitutive components of cytoplasmic mRNA metabolism in trypanosomes with a putative role in translational repression (62). The tight association of *Tb*SCD6 with *Tb*PRMT1 suggests that *Tb*SCD6 is likely to play a role in some of the changes we observe on the proteome level.

*Tb*PRMT1 could also be involved in directly regulating the functions of metabolic enzymes in the affected pathways. Glycolysis is the main pathway that provides energy for BF *T. brucei* cells (63). Upon knockout of ENZ, we see approximately a 50% decrease in hexokinase 2 (*Tb*HK2) and phosphoglucose isomerase levels. We also noted a 40% decrease in levels of alanine aminotransferase, an enzyme responsible for conversion of pyruvate to alanine, a pathway that is extensively utilized in BF trypanosomes (26). Together, these data suggest a decrease in glycolytic flux, and direct measurement of the impact of *Tb*PRMT1 knockout on the glycolytic rate is a future focus. Hexokinase catalyzes a virtually irreversible reaction that commits glucose to glycolysis. *T. brucei*

carries two genes with hexokinase homology that are 98% identical at the amino acid level, *TbHK1* and *TbHK2*. Unlike in other eukaryotes where hexokinases function as dimers, *TbHKs* form hexameric complexes, and they were isolated from cells as a heterohexamer containing an unknown ratio of *TbHK1* and *TbHK2* (64). *T. brucei* further differs from mammals in that *TbHK* is not inhibited by its product, glucose-6-phosphate (65). While *TbHK2* is not active on its own, it gains activity when complexed with inactive *TbHK1* (66). This complex then becomes amenable to inhibition by pyrophosphate, a molecule that has no effect on the *TbHK1* homohexamer (66). These findings suggest that the two enzymes have distinct regulatory mechanisms that differ from the mammalian hexokinase regulation system. A peptide that could originate from either *TbHK1* or *TbHK2* (SKYRFVLPTTKFDLD) was shown to bear arginine dimethylation in our proteome-wide screen; therefore, *TbPRMT1* is likely to contribute to this intricate and unusual pathway for regulation of glycolysis.

We show here that *TbPRMT1* has nucleic acid binding properties and associates with mRNA *in vivo*. Future studies will be focused on determining the functional relevance of this property. One possibility is that *TbPRMT1* can methylate RNA as well as arginines. *TbPRMT1* shares features with the human RNA methyltransferase Mett13/Mett14. Mett13/14 form a heterodimer in which Mett13 is a catalytically active subunit while Mett14 plays a critical structural role necessary for substrate recognition (67). Once *in vivo* RNA targets of *TbPRMT1* are identified, they can be tested as potential substrates. Another possibility is that RNA binding plays a role in defining the appropriate topology of *TbPRMT1* in respect to RNA-/DNA-bound substrates, as in the case of human lysine SET1 methyltransferase (68). Indeed, nucleic acid binding may be a conserved property of PRMT1 enzymes rather than a feature specific to *T. brucei*. PRMT1 was identified among the mRNA-associated proteins in two independent mRNA-bound proteome studies using human hepatocytic HuH-7 cells and human embryonic kidney HEK293 cells (69, 70). Interestingly, human PRMT1 localizes to cytoplasmic granules upon arsenite treatment, suggesting further similarities between the two enzymes (71). Neither *TbPRMT1* nor *HsPRMT1* contains a known RNA binding domain. We identified specific residues in *TbPRMT1* that, when mutated, attenuate its RNA binding activity, suggesting it may be possible to create a nucleic-acid-binding-deficient mutant that could in turn be used to further probe the biological significance of this feature.

In summary, we demonstrate here that *TbPRMT1* affects *T. brucei* virulence, metabolism, and ability to cope with starvation stress. We identified a subset of proteins that change their mRNA association upon *TbPRMT1* depletion, providing new directions for examining the role played by arginine methylation in regulation of RNA binding proteins. Furthermore, we established that *TbPRMT1* itself has the ability to associate with nucleic acids, a finding that may have more widespread implications among PRMT1 homologs. We identified candidate *TbPRMT1* targets that play a role in a broad spectrum of processes, extending the impact of this work to numerous fields of study, such as life cycle progression, translation, stress response, and metabolism regulation. Future studies will be aimed at distinguishing primary effects of *TbPRMT1* loss from downstream proteome changes and deciphering the role that nucleic acid binding plays in *TbPRMT1*'s mechanism of action.

MATERIALS AND METHODS

For details including buffer compositions and antibody sources, please refer to Text S1 in the supplemental material.

***T. brucei* cell culture and cell lines.** PF *T. brucei* strain 29-13 and all cell lines derived from this strain were grown in SM medium supplemented with 10% FBS. The BF SM427 strain was cultured in HMI-11 medium supplemented with 10% FBS. The ENZ KO cell line was created by replacing both ENZ alleles with drug resistance markers. The PRO-MHT cell line contains a tetracycline-inducible C-terminally Myc-His-TAP-tagged PRO construct derived from pLEW100. The PRO-mNG-TY cell line was created using pPOTv6-mNG according to the published protocol (72). The ENZ RNAi cell line was created as described in reference 11.

Statistical analysis. Statistical significance of doubling time differences was calculated using multiple-comparison one-way ANOVA (Fig. 1). Western blot differences were tested by Student's *t* test (Fig. 2 and 3). GO term enrichment *P* values were calculated by Fisher's exact test with Bonferroni correction (Fig. 4A). *P* value of overlap of two protein data sets was determined by R p-hyper function

(Fig. 4B). Significance of differences between amounts of granule-containing cells in uninduced and induced ENZ RNAi cell lines was determined by the chi-square test (Fig. 5). For proteomics data sets, statistical significance between groups was evaluated using a Student *t* test (Table S1 and S2).

Mouse infection assay. Fourteen female CD-1 mice (10 to 12 weeks; Charles River) were infected by intraperitoneal injection with 1×10^5 bloodstream-form *T. brucei* parasites; half were *TbPRMT1* ENZ knockout (ENZ KO; *n* = 7) or SM parental strain (WT; *n* = 7). The course of infection was monitored, and time to death was recorded. Experiments were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Clemson University.

Whole-cell proteome and mRNA-bound proteome. Approximately 4×10^6 cells were harvested, and whole-cell proteomes were quantified as described in Text S1. mRNA-bound proteome purification was performed as described previously, with only minor modifications (30). The protein description in Table 2 includes posttranscriptional activator/repressor annotation that was established by a genome-wide tethering screen (53).

Immunolocalization and fluorescence *in situ* hybridization. NOPP44/46-1 was immunolocalized using antibody against the protein (1:2,000 dilution). FISH was performed using an oligo(dT) probe fused to Alexa Fluor 488 in an overnight (O/N) hybridization protocol.

***In vitro* RNA binding, competition, and EMSA.** A 102-nt RNA fragment of pBluescript SK[−] plasmid sequence was *in vitro* transcribed. A UV-cross-linking-based RNA binding assay was performed as described previously with minor modifications (73). PRMT molarity was determined per dimer in all cases. Affinity for different polynucleotides was determined by adding a mass excess of polynucleotide into the reaction mixture prior to the addition of the protein. To perform EMSA, a 47-nt RNA fragment of the pBluescript SK[−] plasmid was transcribed and incubated with a recombinant protein. Reaction mixtures were resolved on native PAGE.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.02430-18>.

TEXT S1, DOCX file, 0.05 MB.

FIG S1, PDF file, 0.3 MB.

TABLE S1, XLSX file, 1.3 MB.

TABLE S2, XLSX file, 0.1 MB.

TABLE S3, XLSX file, 5.3 MB.

TABLE S4, XLSX file, 0.01 MB.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health grants R01 AI060260 and R21 AI125746 to L.K.R. and P20 GM109094 to K.S.P. and American Heart Association predoctoral fellowship 15PRE24480155 to L.K.

We thank Noreen Williams, Joseph Shlomai, Meredith Morris, and Keith Matthews for donation of antibodies. We acknowledge Jay Bangs and Calvin Tiengwe for consultation and help with fluorescent microscopy.

REFERENCES

- Keating J, Yukich JO, Sutherland CS, Woods G, Tediosi F. 2015. Human African trypanosomiasis prevention, treatment and control costs: a systematic review. *Acta Trop* 150:4–13. <https://doi.org/10.1016/j.actatropica.2015.06.003>.
- Shaw AP, Cecchi G, Wint GR, Mattioli RC, Robinson TP. 2014. Mapping the economic benefits to livestock keepers from intervening against bovine trypanosomiasis in Eastern Africa. *Prev Vet Med* 113:197–210. <https://doi.org/10.1016/j.prevetmed.2013.10.024>.
- Bakker BM, Westerhoff HV, Michels PA. 1995. Regulation and control of compartmentalized glycolysis in bloodstream form *Trypanosoma brucei*. *J Bioenerg Biomembr* 27:513–525. <https://doi.org/10.1007/BF02110191>.
- Mony BM, MacGregor P, Ivens A, Rojas F, Cowton A, Young J, Horn D, Matthews K. 2014. Genome-wide dissection of the quorum sensing signalling pathway in *Trypanosoma brucei*. *Nature* 505:681–685. <https://doi.org/10.1038/nature12864>.
- Mantilla BS, Marchese L, Casas-Sanchez A, Dyer NA, Ejeh N, Biran M, Bringaud F, Lehane MJ, Acosta-Serrano A, Silber AM. 2017. Proline metabolism is essential for *Trypanosoma brucei* survival in the tsetse vector. *PLoS Pathog* 13:e1006158. <https://doi.org/10.1371/journal.ppat.1006158>.
- Michaeli S. 2011. Trans-splicing in trypanosomes: machinery and its impact on the parasite transcriptome. *Future Microbiol* 6:459–474. <https://doi.org/10.2217/fmb.11.20>.
- Lott K, Li J, Fisk JC, Wang H, Aletta JM, Qu J, Read LK. 2013. Global proteomic analysis in trypanosomes reveals unique proteins and conserved cellular processes impacted by arginine methylation. *J Proteomics* 91:210–225. <https://doi.org/10.1016/j.jprot.2013.07.010>.
- Fisk JC, Li J, Wang H, Aletta JM, Qu J, Read LK. 2013. Proteomic analysis reveals diverse classes of arginine methylproteins in mitochondria of trypanosomes. *Mol Cell Proteomics* 12:302–311. <https://doi.org/10.1074/mcp.M112.022533>.
- Larsen SC, Sylvestersen KB, Mund A, Lyon D, Mullari M, Madsen MV, Daniel JA, Jensen LJ, Nielsen ML. 2016. Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells. *Sci Signal* 9:rs9. <https://doi.org/10.1126/scisignal.aaf7329>.
- Bedford MT. 2007. Arginine methylation at a glance. *J Cell Sci* 120:4243–4246. <https://doi.org/10.1242/jcs.019885>.
- Lott K, Zhu L, Fisk JC, Tomasello DL, Read LK. 2014. Functional interplay between protein arginine methyltransferases in *Trypanosoma brucei*. *Microbiologyopen* 3:595–609. <https://doi.org/10.1002/mbo3.191>.
- Pelletier M, Pasternack DA, Read LK. 2005. *In vitro* and *in vivo* analysis of the major type I protein arginine methyltransferase from *Trypanosoma*

- brucei. *Mol Biochem Parasitol* 144:206–217. <https://doi.org/10.1016/j.molbiopara.2005.08.015>.
13. Kafková L, Deblér EW, Fisk JC, Jain K, Clarke SG, Read LK. 2017. The major protein arginine methyltransferase in *Trypanosoma brucei* functions as an enzyme-prozyme complex. *J Biol Chem* 292:2089–2100. <https://doi.org/10.1074/jbc.M116.757112>.
 14. Goulah CC, Read LK. 2007. Differential effects of arginine methylation on RBP16 mRNA binding, guide RNA (gRNA) binding, and gRNA-containing ribonucleoprotein complex (gRNP) formation. *J Biol Chem* 282: 7181–7190. <https://doi.org/10.1074/jbc.M609485200>.
 15. Goulah CC, Pelletier M, Read LK. 2006. Arginine methylation regulates mitochondrial gene expression in *Trypanosoma brucei* through multiple effector proteins. *RNA* 12:1545–1555. <https://doi.org/10.1261/ma.90106>.
 16. Lott K, Mukhopadhyay S, Li J, Wang J, Yao J, Sun Y, Qu J, Read LK. 2015. Arginine methylation of DRBD18 differentially impacts its opposing effects on the trypanosome transcriptome. *Nucleic Acids Res* 43: 5501–5523. <https://doi.org/10.1093/nar/gkv428>.
 17. Lee WC, Lin WL, Matsui T, Chen ES, Wei TY, Lin WH, Hu H, Zheng YG, Tsai MD, Ho MC. 2015. Protein arginine methyltransferase 8: tetrameric structure and protein substrate specificity. *Biochemistry* 54:7514–7523. <https://doi.org/10.1021/acs.biochem.5b00995>.
 18. Toma-Fukai S, Kim JD, Park KE, Kuwabara N, Shimizu N, Krayukhina E, Uchiyama S, Fukamizu A, Shimizu T. 2016. Novel helical assembly in arginine methyltransferase 8. *J Mol Biol* 428:1197–1208. <https://doi.org/10.1016/j.jmb.2016.02.007>.
 19. Zhang X, Cheng X. 2003. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. *Structure* 11:509–520. [https://doi.org/10.1016/S0969-2126\(03\)00071-6](https://doi.org/10.1016/S0969-2126(03)00071-6).
 20. Tang J, Gary JD, Clarke S, Herschman HR. 1998. PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. *J Biol Chem* 273:16935–16945. <https://doi.org/10.1074/jbc.273.27.16935>.
 21. Dhar S, Vemulapalli V, Patananan AN, Huang GL, Di Lorenzo A, Richard S, Comb MJ, Guo A, Clarke SG, Bedford MT. 2013. Loss of the major type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs. *Sci Rep* 3:1311. <https://doi.org/10.1038/srep01311>.
 22. Yu MC. 2011. The role of protein arginine methylation in mRNP dynamics. *Mol Biol Int* 2011:163827. <https://doi.org/10.4061/2011/163827>.
 23. Rho J, Choi S, Jung CR, Im DS. 2007. Arginine methylation of Sam68 and SLM proteins negatively regulates their poly(U) RNA binding activity. *Arch Biochem Biophys* 466:49–57. <https://doi.org/10.1016/j.abb.2007.07.017>.
 24. Cui W, Yoneda R, Ueda N, Kurokawa R. 2018. Arginine methylation of translocated in liposarcoma (TLS) inhibits its binding to long noncoding RNA, abrogating TLS-mediated repression of CBP/p300 activity. *J Biol Chem* 293:10937–10948. <https://doi.org/10.1074/jbc.RA117.000598>.
 25. Das A, Bellofatto V, Rosenfeld J, Carrington M, Romero-Zalaz R, del Val C, Estévez AM. 2015. High throughput sequencing analysis of *Trypanosoma brucei* DRBD3/PTB1-bound mRNAs. *Mol Biochem Parasitol* 199: 1–4. <https://doi.org/10.1016/j.molbiopara.2015.02.003>.
 26. Creek DJ, Mazet M, Achcar F, Anderson J, Kim DH, Kamour R, Morand P, Millerioux Y, Biran M, Kerkhoven EJ, Chokkathukalam A, Weidt SK, Burgess KE, Breiting R, Watson DG, Bringaud F, Barrett MP. 2015. Probing the metabolic network in bloodstream-form *Trypanosoma brucei* using untargeted metabolomics with stable isotope labelled glucose. *PLoS Pathog* 11:e1004689. <https://doi.org/10.1371/journal.ppat.1004689>.
 27. Baker N, Glover L, Munday JC, Aguinaga Andres D, Barrett MP, de Koning HP, Horn D. 2012. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. *Proc Natl Acad Sci U S A* 109:10996–11001. <https://doi.org/10.1073/pnas.1202885109>.
 28. Urbaniak MD, Guthrie ML, Ferguson MA. 2012. Comparative SILAC proteomic analysis of *Trypanosoma brucei* bloodstream and procyclic life-cycle stages. *PLoS One* 7:e36619. <https://doi.org/10.1371/journal.pone.0036619>.
 29. Dean S, Marchetti R, Kirk K, Matthews KR. 2009. A surface transporter family conveys the trypanosome differentiation signal. *Nature* 459: 213–217. <https://doi.org/10.1038/nature07997>.
 30. Lueong S, Merce C, Fischer B, Hoheisel JD, Erben ED. 2016. Gene expression regulatory networks in *Trypanosoma brucei*: insights into the role of the mRNA-binding proteome. *Mol Microbiol* 100:457–471. <https://doi.org/10.1111/mmi.13328>.
 31. Freire ER, Malvezzi AM, Vashisht AA, Zuberek J, Saada EA, Langousis G, Nascimento JD, Moura D, Darzynkiewicz E, Hill K, de Melo Neto OP, Wohlschlegel JA, Sturm NR, Campbell DA. 2014. *Trypanosoma brucei* translation initiation factor homolog EIF4E6 forms a tripartite cytosolic complex with EIF4G5 and a capping enzyme homolog. *Eukaryot Cell* 13:896–908. <https://doi.org/10.1128/EC.00071-14>.
 32. Jensen BC, Brekken DL, Randall AC, Kifer CT, Parsons M. 2005. Species specificity in ribosome biogenesis: a nonconserved phosphoprotein is required for formation of the large ribosomal subunit in *Trypanosoma brucei*. *Eukaryot Cell* 4:30–35. <https://doi.org/10.1128/EC.4.1.30-35.2005>.
 33. Hellman K, Prohaska K, Williams N. 2007. *Trypanosoma brucei* RNA binding proteins p34 and p37 mediate NOPP44/46 cellular localization via the exportin 1 nuclear export pathway. *Eukaryot Cell* 6:2206–2213. <https://doi.org/10.1128/EC.00176-07>.
 34. Fritz M, Vanselow J, Sauer N, Lamer S, Goos C, Siegel TN, Subota I, Schlosser A, Carrington M, Kramer S. 2015. Novel insights into RNP granules by employing the trypanosome's microtubule skeleton as a molecular sieve. *Nucleic Acids Res* 43:8013–8032. <https://doi.org/10.1093/nar/gkv731>.
 35. Cristodero M, Schimanski B, Heller M, Roditi I. 2014. Functional characterization of the trypanosome translational repressor SCD6. *Biochem J* 457:57–67. <https://doi.org/10.1042/BJ20130747>.
 36. Bedford MT, Clarke SG. 2009. Protein arginine methylation in mammals: who, what, and why. *Mol Cell* 33:1–13. <https://doi.org/10.1016/j.molcel.2008.12.013>.
 37. Yang Y, Bedford MT. 2013. Protein arginine methyltransferases and cancer. *Nat Rev Cancer* 13:37–50. <https://doi.org/10.1038/nrc3409>.
 38. Auclair Y, Richard S. 2013. The role of arginine methylation in the DNA damage response. *DNA Repair (Amst)* 12:459–465. <https://doi.org/10.1016/j.dnarep.2013.04.006>.
 39. Poulard C, Corbo L, Le Romancer M. 2016. Protein arginine methylation/demethylation and cancer. *Oncotarget* 7:67532–67550. <https://doi.org/10.18632/oncotarget.11376>.
 40. Kim JH, Yoo BC, Yang WS, Kim E, Hong S, Cho JY. 2016. The role of protein arginine methyltransferases in inflammatory responses. *Mediators Inflamm* 2016:4028353. <https://doi.org/10.1155/2016/4028353>.
 41. Blanc RS, Richard S. 2017. Arginine methylation: the coming of age. *Mol Cell* 65:8–24. <https://doi.org/10.1016/j.molcel.2016.11.003>.
 42. Ferreira TR, Alves-Ferreira EV, Defina TP, Walrad P, Papadopoulos B, Cruz AK. 2014. Altered expression of an RBP-associated arginine methyltransferase 7 in *Leishmania major* affects parasite infection. *Mol Microbiol* . <https://doi.org/10.1111/mmi.12819>.
 43. Vickerman K. 1985. Developmental cycles and biology of pathogenic trypanosomes. *Br Med Bull* 41:105–114. <https://doi.org/10.1093/oxfordjournals.bmb.a072036>.
 44. Bauer S, Morris JC, Morris MT. 2013. Environmentally regulated glycosome protein composition in the African trypanosome. *Eukaryot Cell* 12:1072–1079. <https://doi.org/10.1128/EC.00086-13>.
 45. Giffin BF, McCann PP, Bitonti AJ, Bacchi CJ. 1986. Polyamine depletion following exposure to DL-alpha-difluoromethylornithine both in vivo and in vitro initiates morphological alterations and mitochondrial activation in a monomorphic strain of *Trypanosoma brucei*. *J Protozool* 33:238–243. <https://doi.org/10.1111/j.1550-7408.1986.tb05599.x>.
 46. Giffin BF, McCann PP. 1989. Physiological activation of the mitochondrion and the transformation capacity of DFMO induced intermediate and short stumpy bloodstream form trypanosomes. *Am J Trop Med Hyg* 40:487–493. <https://doi.org/10.4269/ajtmh.1989.40.487>.
 47. Tonelli RR, Augusto LDS, Castilho BA, Schenkman S. 2011. Protein synthesis attenuation by phosphorylation of eIF2alpha is required for the differentiation of *Trypanosoma cruzi* into infective forms. *PLoS One* 6:e27904. <https://doi.org/10.1371/journal.pone.0027904>.
 48. Romaniuk MA, Frasc AC, Cassola A. 2018. Translational repression by an RNA-binding protein promotes differentiation to infective forms in *Trypanosoma cruzi*. *PLoS Pathog* 14:e1007059. <https://doi.org/10.1371/journal.ppat.1007059>.
 49. Luu VD, Brems S, Hoheisel JD, Burchmore R, Guilbride DL, Clayton C. 2006. Functional analysis of *Trypanosoma brucei* PUF1. *Mol Biochem Parasitol* 150:340–349. <https://doi.org/10.1016/j.molbiopara.2006.09.007>.
 50. D'Archivio S, Wickstead B. 2017. Trypanosome outer kinetochore proteins suggest conservation of chromosome segregation machinery across eukaryotes. *J Cell Biol* 216:379–391. <https://doi.org/10.1083/jcb.201608043>.
 51. Mony BM, Matthews KR. 2015. Assembling the components of the quorum sensing pathway in African trypanosomes. *Mol Microbiol* 96: 220–232. <https://doi.org/10.1111/mmi.12949>.

52. Estevez AM. 2008. The RNA-binding protein TbDRBD3 regulates the stability of a specific subset of mRNAs in trypanosomes. *Nucleic Acids Res* 36:4573–4586. <https://doi.org/10.1093/nar/gkn406>.
53. Erben ED, Fadda A, Lueong S, Hoheisel JD, Clayton C. 2014. A genome-wide tethering screen reveals novel potential post-transcriptional regulators in *Trypanosoma brucei*. *PLoS Pathog* 10:e1004178. <https://doi.org/10.1371/journal.ppat.1004178>.
54. Fernández-Moya SM, García-Pérez A, Kramer S, Carrington M, Estévez AM. 2012. Alterations in DRBD3 ribonucleoprotein complexes in response to stress in *Trypanosoma brucei*. *PLoS One* 7:e48870. <https://doi.org/10.1371/journal.pone.0048870>.
55. Rajyaguru P, She M, Parker R. 2012. Scd6 targets eIF4G to repress translation: RGG motif proteins as a class of eIF4G-binding proteins. *Mol Cell* 45:244–254. <https://doi.org/10.1016/j.molcel.2011.11.026>.
56. Kilchert C, Weidner J, Prescianotto-Baschong C, Spang A. 2010. Defects in the secretory pathway and high Ca^{2+} induce multiple P-bodies. *Mol Biol Cell* 21:2624–2638. <https://doi.org/10.1091/mbc.e10-02-0099>.
57. Iwaki A, Izawa S. 2012. Acidic stress induces the formation of P-bodies, but not stress granules, with mild attenuation of bulk translation in *Saccharomyces cerevisiae*. *Biochem J* 446:225–233. <https://doi.org/10.1042/BJ20120583>.
58. Matsumoto K, Nakayama H, Yoshimura M, Masuda A, Dohmae N, Matsumoto S, Tsujimoto M. 2012. PRMT1 is required for RAP55 to localize to processing bodies. *RNA Biol* 9:610–623. <https://doi.org/10.4161/rna.19527>.
59. Lien PT, Izumikawa K, Muroi K, Irie K, Suda Y, Irie K. 2016. Analysis of the physiological activities of Scd6 through its interaction with Hmt1. *PLoS One* 11:e0164773. <https://doi.org/10.1371/journal.pone.0164773>.
60. Poornima G, Shah S, Vignesh V, Parker R, Rajyaguru PI. 2016. Arginine methylation promotes translation repression activity of eIF4G-binding protein, Scd6. *Nucleic Acids Res* 44:9358–9368. <https://doi.org/10.1093/nar/gkw762>.
61. Tanaka KJ, Ogawa K, Takagi M, Imamoto N, Matsumoto K, Tsujimoto M. 2006. RAP55, a cytoplasmic mRNP component, represses translation in *Xenopus* oocytes. *J Biol Chem* 281:40096–40106. <https://doi.org/10.1074/jbc.M609059200>.
62. Cassola A. 2011. RNA granules living a post-transcriptional life: the trypanosomes' case. *Curr Chem Biol* 5:108–117. <https://doi.org/10.2174/2212796811105020108>.
63. Smith TK, Bringaud F, Nolan DP, Figueiredo LM. 2017. Metabolic reprogramming during the *Trypanosoma brucei* life cycle. *F1000Res* 6:F1000 Faculty Rev-683. <https://doi.org/10.12688/f1000research.10342.2>.
64. Ortega-Atienza S, Rubis B, McCarthy C, Zhitkovich A. 2016. Formaldehyde is a potent proteotoxic stressor causing rapid heat shock transcription factor 1 activation and Lys48-linked polyubiquitination of proteins. *Am J Pathol* 186:2857–2868. <https://doi.org/10.1016/j.ajpath.2016.06.022>.
65. Nwagwu M, Oppenheimer FR. 1982. Regulation of glycolysis in *Trypanosoma brucei*: hexokinase and phosphofructokinase activity. *Acta Trop* 39:61–72.
66. Chambers JW, Kearns MT, Morris MT, Morris JC. 2008. Assembly of heterohexameric trypanosome hexokinases reveals that hexokinase 2 is a regulable enzyme. *J Biol Chem* 283:14963–14970. <https://doi.org/10.1074/jbc.M802124200>.
67. Wang P, Dostader KA, Nam Y. 2016. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. *Mol Cell* 63:306–317. <https://doi.org/10.1016/j.molcel.2016.05.041>.
68. Luciano P, Jeon J, El-Kaoutari A, Challal D, Bonnet A, Barucco M, Candelli T, Jourquin F, Lesage P, Kim J, Libri D, Géli V. 2017. Binding to RNA regulates Set1 function. *Cell Discov* 3:17040. <https://doi.org/10.1038/celldisc.2017.40>.
69. Beckmann BM, Horos R, Fischer B, Castello A, Eichelbaum K, Alleaume AM, Schwarzl T, Curk T, Foehr S, Huber W, Krijgsvelde J, Hentze MW. 2015. The RNA-binding proteomes from yeast to man harbour conserved enigmRBPs. *Nat Commun* 6:10127. <https://doi.org/10.1038/ncomms10127>.
70. Baltz AG, Munschauer M, Schwanhauser B, Vasile A, Murakawa Y, Schueler M, Youngs N, Penfold-Brown D, Drew K, Milek M, Wyler E, Bonneau R, Selbach M, Dieterich C, Landthaler M. 2012. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. *Mol Cell* 46:674–690. <https://doi.org/10.1016/j.molcel.2012.05.021>.
71. Tsai WC, Gayatri S, Reineke LC, Sbardella G, Bedford MT, Lloyd RE. 2016. Arginine demethylation of G3BP1 promotes stress granule assembly. *J Biol Chem* 291:22671–22685. <https://doi.org/10.1074/jbc.M116.739573>.
72. Dean S, Sunter J, Wheeler RJ, Hodkinson I, Gluenz E, Gull K. 2015. A toolkit enabling efficient, scalable and reproducible gene tagging in trypanosomatids. *Open Biol* 5:140197. <https://doi.org/10.1098/rsob.140197>.
73. Kafková L, Ammerman ML, Faktorova D, Fisk JC, Zimmer SL, Sobotka R, Read LK, Lukes J, Hashimi H. 2012. Functional characterization of two paralogs that are novel RNA binding proteins influencing mitochondrial transcripts of *Trypanosoma brucei*. *RNA* 18:1846–1861. <https://doi.org/10.1261/ra.033852.112>.